ClinicalTrials.gg
RecruitingNCT04940000Updated Nov 18, 2026

Evaluation of the Interest of a Video-assisted Remote Speech Therapy Consultation in Patients With ORL Cancer (TELE ORTHOPHONIE)

An interventional study of Patient managed at the IUCT-O and by a private speech therapist (near the patient's home). in ORL Cancer, sponsored by Institut Claudius Regaud. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Institut Claudius Regaud · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Interventional, prospective, single-centre study aimed to evaluate the impact of a video-assisted remote speech therapy consultation in relation to the complexity and specificity of the care of patients with ORL cancer. Three indications will be studied: phonation problems, swallowing problems and other problems.

The study will be conducted on a population of patients with T3, T4 ORL cancer requiring speech therapy.

Each patient included will have a video-assisted speech therapy consultation with a private speech therapist and an expert speech therapist. At the end of this video consultation, the patient and the private speech therapist will be asked to complete a satisfaction questionnaire.

At the follow-up visit following the video-assisted consultation, the patient will have completed participation in the study.

02

Conditions studied

  • ORL Cancer

Keywords

  • Video-Assisted Speech Therapy
03

In context

Lead sponsor

Institut Claudius Regaud is the lead sponsor of 117 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years at study entry.
  2. Patient with carcinological pathology of the VADS, relevant to surgery and/or radiotherapy and/or chemotherapy.
  3. Patient managed at the IUCT-O and by a private speech therapist (near the patient's home).
  4. Patient affiliated to a Social Security system in France.
  5. Patient having signed prior to inclusion in the study and prior to any specific study procedure.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. Any psychological, familial, geographical or sociological condition that does not allow for compliance with the medical follow-up and/or procedures foreseen in the study protocol.
  3. Patients deprived of their liberty or under legal protection (guardianship and tutorship, safeguard of justice).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Patient with T3-T4 ORL cancer, relevant to surgery and/or radiotherapy and/or chemotherapy.

    Other: Patient managed at the IUCT-O and by a private speech therapist (near the patient's home).

Interventions

  • OtherPatient managed at the IUCT-O and by a private speech therapist (near the patient's home).

    Each patient included will have a video-assisted remote speech therapy consultation with a private speech therapist (near the patient's home) and the expert speech therapist of IUCT-O center. At the end of this video consultation, the patient and the private speech therapist will be asked to complete a satisfaction questionnaire.

06

What researchers measure

Primary outcomes

  1. The rate of patients for whom tele-therapy will be considered successful.

    Time frame: 12 months for each patient

Secondary outcomes

  1. The rate of patients with full or partial resolution of speech-language pathology at the end of the telecare consultation.

    Time frame: 12 months for each patient

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Sep 2028, 84 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2021
First posted
Jun 25, 2021
StartActual
Sep 2, 2021
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04940000
Responsible party
Sponsor
First posted
Jun 25, 2021
Start date
Sep 2, 2021
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Jérôme SARINI
Contact
sarini.jerome@iuct-oncopole.fr
05 31 15 60 16
Jean-Claude FARENC
Contact
farenc.jean-claude@iuct-oncopole.fr
05 31 15 51 97

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion